SCHEMBL16239013

SCHEMBL16239013

O=C1CN=C(c2cccc(NS(=O)(=O)c3ccccc3)c2)c2ccc3ccccc3c2N1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 4/20 0.54
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
MMP13 P45452 1/20 0.44
LMNA P02545 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
PFKFB3 Q16875 2/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
MET P08581 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30297281 1.00 P2RX4 (0.54) P2RX4MMP2MMP9MMP8MMP13
SCHEMBL16796597 0.82 MMP2 (0.49) P2RX4MMP2MMP9MMP8MMP13
SCHEMBL18661904 0.81 P2RX4 (0.60) P2RX4LMNAALDH1A1HPGDPDE4A
SCHEMBL16239089 0.78 P2RX4 (0.61) P2RX4LMNAHTTKMT2APDE4D
SCHEMBL16239231 0.78 P2RX4 (0.50) P2RX4LMNAALDH1A1HPGDKMT2A
SCHEMBL2681057 0.78 P2RX4 (0.50) P2RX4LMNAHPGDKMT2APDE4D
SCHEMBL23094055 0.77 P2RX4 (0.50) P2RX4LMNAALDH1A1HPGDKMT2A
SCHEMBL2680321 0.76 P2RX4 (0.54) P2RX4ALDH1A1HPGDKMT2A
SCHEMBL30526426 0.74 P2RX4 (0.49) P2RX4LMNAALDH1A1HPGDKMT2A
SCHEMBL2682170 0.74 P2RX4 (0.52) P2RX4LMNAHTTHSP90AA1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TAKASAKI UNIV OF HEALTH AND WELFARE (JP) 2026-01-01 US claimed
US-20250375456-A1 AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE NIPPON CHEMIPHAR CO (JP) 2025-12-11 US claimed
US-20250241927-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN NIPPON CHEMIPHAR CO (JP) 2025-07-31 US claimed
EP-4501357-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS Takasaki University of Health and Welfare (JP) 2025-02-05 EP claimed
WO-2024177158-A1 SOLID DISPERSION OF COMPOUND HAVING P2X4 RECEPTOR ANTAGONISM 日本ケミファ株式会社 2024-08-29 WO claimed
EP-4410310-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES Nippon Chemiphar Co., Ltd. (JP) 2024-08-07 EP claimed
US-11918589-B2 Medicament for treatment of multiple sclerosis NIPPON CHEMIPHAR CO., LTD. (JP) 2024-03-05 US claimed
WO-2023190826-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS 学校法人 高崎健康福祉大学 2023-10-05 WO claimed
US-20230277552-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION NIPPON CHEMIPHAR CO., LTD. (JP) 2023-09-07 US claimed
WO-2023157895-A1 PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR ENDOMETRIOSIS OR ADENOMYOSIS 国立大学法人 鳥取大学 2023-08-24 WO claimed
EP-4129296-A1 DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE Università di Pisa (IT) 2023-02-08 EP claimed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US claimed
EP-3848051-A1 MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY Nippon Chemiphar Co., Ltd. (JP) 2021-07-14 EP claimed
US-20210205326-A1 MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY NIPPON CHEMIPHAR CO., LTD. (JP) 2021-07-08 US claimed
US-20210121478-A1 MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS NIPPON CHEMIPHAR CO., LTD. (JP) 2021-04-29 US claimed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US claimed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 US claimed
WO-2019177117-A1 DRUG FOR TREATING COUGH 日本ケミファ株式会社 2019-09-19 WO claimed
EP-2803662-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2017-03-01 EP claimed
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2016-09-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375456-A1 AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE P2RX5, P2RX3, P2RX2 P2RX4 7/4885MMP2 2640/4885MMP9 2487/4885
US-20210121478-A1 MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS TRPM4, TRPM7, P2RX3 P2RX4 5/4885MMP2 1726/4885MMP9 2328/4885
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 6/4885MMP2 4485/4885MMP9 4806/4885
US-20210205326-A1 MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY P2RX4, P2RX3, P2RX1 P2RX4 1/4885MMP2 1337/4885MMP9 1341/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 6/4885MMP2 4482/4885MMP9 4809/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 P2RX4 6/4885MMP2 4482/4885MMP9 4809/4885
US-11918589-B2 Medicament for treatment of multiple sclerosis P2RX3, TRPM4, P2RX4 P2RX4 3/4885MMP2 1846/4885MMP9 2528/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 P2RX4 6/4885MMP2 4482/4885MMP9 4809/4885
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TRPV1, TRPV4, TRPV5 P2RX4 15/4885MMP2 4089/4885MMP9 4256/4885
US-20230277552-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION P2RX5, P2RX3, P2RX2 P2RX4 4/4885MMP2 3942/4885MMP9 2139/4885
US-20250241927-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN P2RX3, TRPV1, P2RX2 P2RX4 5/4885MMP2 2093/4885MMP9 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.